Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding.

Berkower I, Patel C, Ni Y, Virnik K, Xiang Z, Spadaccini A.

Virology. 2008 Aug 1;377(2):330-8. doi: 10.1016/j.virol.2008.03.040. Epub 2008 Jun 2.

2.

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24. Erratum in: J Virol. 2015 Jun;89(12):6526.

3.

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R.

Virology. 2003 Sep 1;313(2):387-400.

5.

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD.

Science. 2009 Nov 20;326(5956):1123-7. doi: 10.1126/science.1175868.

6.
7.
9.

Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.

Pantophlet R, Wilson IA, Burton DR.

Protein Eng Des Sel. 2004 Oct;17(10):749-58. Epub 2004 Nov 12.

PMID:
15542540
10.

Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.

Posner MR, Cavacini LA, Emes CL, Power J, Byrn R.

J Acquir Immune Defic Syndr. 1993 Jan;6(1):7-14.

PMID:
8417177
11.

Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.

Gift SK, Zentner IJ, Schön A, McFadden K, Umashankara M, Rajagopal S, Contarino M, Duffy C, Courter JR, Zhang MY, Gershoni JM, Cocklin S, Dimitrov DS, Smith AB 3rd, Freire E, Chaiken IM.

Biochemistry. 2011 Apr 12;50(14):2756-68. doi: 10.1021/bi101160r. Epub 2011 Mar 18.

12.

Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120.

Shrivastava IH, Wendel K, LaLonde JM.

Biochemistry. 2012 Oct 2;51(39):7783-93. doi: 10.1021/bi300878d. Epub 2012 Sep 21.

13.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

14.

Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.

Ditzel HJ, Binley JM, Moore JP, Sodroski J, Sullivan N, Sawyer LS, Hendry RM, Yang WP, Barbas CF 3rd, Burton DR.

J Immunol. 1995 Jan 15;154(2):893-906.

PMID:
7529290
15.

HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.

16.

Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.

Qiao Y, Man L, Qiu Z, Yang L, Sun Y, He Y.

Antiviral Res. 2016 Aug;132:252-61. doi: 10.1016/j.antiviral.2016.06.013. Epub 2016 Jul 5.

PMID:
27387828
17.

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 7.

18.

Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.

Chakraborty K, Durani V, Miranda ER, Citron M, Liang X, Schleif W, Joyce JG, Varadarajan R.

Biochem J. 2006 Nov 1;399(3):483-91.

19.

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR.

J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.

20.

Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.

Prabakaran P, Gan J, Wu YQ, Zhang MY, Dimitrov DS, Ji X.

J Mol Biol. 2006 Mar 17;357(1):82-99. Epub 2006 Jan 9.

PMID:
16426633

Supplemental Content

Support Center